Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a conditional marketing authorization for V920 Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP, live).
Language:
English
Contact:
Media:
Pamela Eisele
267-305-3558
Skip Irvine
267-305-0338
Investors:
Peter Dannenbaum
908-740-1037
Michael DeCarbo
908-740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck